Tagworks Pharmaceuticals Announces $65 Million in Series A Financing led by Ysios Capital and Gilde Healthcare, to Advance Click-to-Release Therapeutics

by Ysios Capital

Tagworks Pharmaceuticals BV (“Tagworks”), the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financin...

Read more

Disruptive phase I combination trial design: implementing patient-centric personalized treatment approaches

by VHIO

VHIO researchers publish an editorial on the preliminary results of a phase 1 clinical trial testing a novel SHP2 inhibitor. The clinical trial data discussed in the editorial represent a paradigm shi...

Read more

Drug prevents infection with SARS-CoV-2 and other coronaviruses in preclinical models

by IrsiCaixa

β-cyclodextrins prevent SARS-CoV-2 and HCoV-229E infection in cell cultures, primary tissues and animal model

Read more

El fármaco experimental vorasidenib mejora la supervivencia de pacientes con glioma y determinado perfil genético

by Revista Genética Médica

El fármaco experimental vorasidenib retrasa el crecimiento de los gliomas con mutaciones en genes IDH, concluye un ensayo clínico realizado por investigadores del Memorial Sloan Kettering Cancer Cen...

Read more

OncoDNA Announces the Closing of a Round C financing of 6,5 M€

by OncoDNA

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 ...

Read more

IDP Pharma starts clinical trials of its first-in-class IDP-121 drug in hematological cancers and opens a financing round of €1M for the first phase of the study

by Parc Científic de Barcelona

The Spanish Agency of Medicines and Medical Devices has authorised the clinical trial of IDP-121, the first drug blocking and degrading a key oncoprotein in several hematological tumors, including mul...

Read more

Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).

Read more

Nanopartículas para el tratamiento de la enfermedad del ojo seco

by Fundació Bosch i Gimpera

El síndrome del ojo seco es una enfermedad multifactorial de la superficie ocular caracterizada por la pérdida de la película lagrimal y el deterioro de su calidad, que producen en muchos casos una...

Read more

The evolution of Pharmaceutical Industry: Beyond the Pill

by GENESIS Biomed

Beyond the Pill es un término holístico centrada en el paciente donde la salud y bienestar de una persona va más allá de simplemente tomar una píldora o medicamento y engloba la tecnología de la...

Read more

New collaboration agreement with the ICR and Vivan Therapeutics to design new personalized treatments against cancer

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

A collaboration has been signed between the Bellvitge Biomedical Research Institute (IDIBELL), the Institute of Cancer Research (ICR) in London, and Vivan Therapeutics to jointly develop molecules tha...

Read more

A combination therapy, new option for patients with advanced urothelial cancer who cannot receive conventional chemotherapy

by Hospital de la Santa Creu i Sant Pau

Researcher has been able to verify that the combination of two drugs, enfortumab vedotin and pembrolizumab, which had previously shown benefits in survival in second-line treatment and in cases of adv...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Xeltis receives IDE approval from FDA fo...

by Ysios Capital

aXess is a restorative arteriovenous dialysis conduit which allows vas...

Photos Stream